Medical Pharmacology Practice Questions: Chapter 33-34 Protein Tyrosine Kinase Inhibitors of VEGFR: lenvatinib (Lenvima)

Medical Pharmacology Practice Questions: Protein Tyrosine Kinase Inhibitors of VEGFR and other receptors: lenvatinib (Lenvima)

Lenvatinib inhibits differentiated thyroid cancer tumor growth because of the drug's antiangiogenic activity.
1. True
2. False
Lenvatinib enzyme inhibitory profile/profiles:
1. Inhibits protein kinase activities of VEGFR-1 (Vascular Endothelial Growth Factor)
2. Inhibits protein kinase activities of VEGFR-2 (Vascular Endothelial Growth Factor)
3. Inhibits protein kinase activities of VEGFR-3. (Vascular Endothelial Growth Factor)
4. A & B
5. B & C
6. A & C
7. A, B & C
Lenvatinib inhibits which one(s) of the following receptor kinases involved in pathologic angiogenesis and cancer progression.
1. FGFRs (Fiberblast Growth Factor Receptors)
2. PDGFR (Platelet-derived Growth Factor Receptors)
3. Both
4. Neither
Lenvatinib (Lenvima) clinical application/applications:
1. Recurrent or metastatic thyroid cancer (differentiated).
2. In therapeutic combination with everolimus in treating patients with advanced renal cell carcinoma (RCC).
3. Both
Combination of everolimus (mTOR inhibitor) and lenvatinib increased antiangiogenic/antitumor activity compared to either drug used alone by:
1. Reducing endothelial cell division
2. Reducing tube formation
3. Decreasing VEGF signaling
4. A & B
5. B & C
6. A & C
7. A, B & C
Lenvatinib pharmacodynamic/kinetics:
1. Oral absorption
2. High-protein binding (about 98%)
3. Both
4. Neither
Lenvatinib pharmacodynamic/kinetics: Metabolism
1. Hepatic metabolism through CYP3A isoforms
2. Metabolism by aldehyde oxidase.
3. Both
4. Neither
Lenvatinib adverse effects (major):
1. Hypertension
2. Hemorrhagic events
3. Both
4. Neither
Lenvatinib administration in pregnancy may result in fetal harm. Therefore females of reproductive potential should employ effective contraception not only during lenvatinib treatment but for at least a month following completion of treatment.
1. True
2. False
With oral administration, lenvatinib exhibits some emetic properties; therefore antiemetics may be appropriate to limit nausea and vomiting.
1. True
2. False